Necitumumab Effective for NSCLC

Share this content:
Necitumumab Effective for NSCLC
Necitumumab Effective for NSCLC

Eli Lilly and Company announced results from the largest Phase 3 SQUIRE trial of necitumumab (IMC-11F8) for the first-line treatment of squamous non-small cell lung cancer (NSCLC). Necitumumab is a recombinant human IgG1 monoclonal antibody designed to target the human epidermal growth factor receptor 1 (EGFR).

The SQUIRE study enrolled 1,093 patients with histologically- or cytologically-confirmed, stage IV squamous NSCLC, who had received no prior therapy for metastatic disease. Patients were randomized to receive first-line necitumumab plus chemotherapy consisting of gemcitabine and cisplatin in study Arm A, or gemcitabine-cisplatin chemotherapy alone in study Arm B. Patients underwent radiographic assessment of disease status every six weeks (± 3 days), until radiographic documentation of progressive disease (PD). The primary endpoint was overall survival.

RELATED: Lung Cancer Resource Center

Patients with stage IV metastatic squamous NSCLC demonstrated a statistically significant improvement in overall survival (HR=0.84, P=0.012) with a median survival of 11.5 months when receiving necitumumab in combination with gemcitabine and cisplatin as a first-line treatment, as compared to 9.9 months for those treated with chemotherapy alone. Consistent efficacy results were observed across endpoints and subgroups.

Eli Lilly and Company plans to announce additional safety and efficacy results at the American Society of Clinical Oncology (ASCO) Annual Meeting.

For more information call (800) 545-5979 or visit LillyOncology.com.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs